Multivariable analysis
Characteristic . | OS . | EFS . | RFS . | ||||||
---|---|---|---|---|---|---|---|---|---|
HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
Dose group, × 106CAR T cells per kg | .008 | <.001 | .002 | ||||||
0-1.3 | — | — | — | — | — | — | |||
1.3-1.7 | 0.7 | 0.34-1.46 | 0.51 | 0.29-0.88 | 0.4 | 0.19-0.82 | |||
1.7-2.4 | 0.4 | 0.18-0.87 | 0.4 | 0.22-0.73 | 0.43 | 0.2-0.89 | |||
2.4-5.1 | 0.22 | 0.08-0.61 | 0.24 | 0.12-0.49 | 0.18 | 0.07-0.49 | |||
Age at infusion, y | 0.98 | 0.94-1.03 | .4 | 0.97 | 0.94-1.00 | .085 | 0.98 | 0.94-1.03 | .4 |
Preinfusion disease burden overall | <.001 | <.001 | .004 | ||||||
High | — | — | — | — | — | — | |||
Low | 0.38 | 0.15-0.99 | 0.34 | 0.18-0.65 | 0.38 | 0.17-0.88 | |||
No detectable disease | 0.18 | 0.06-0.50 | 0.29 | 0.16-0.52 | 0.38 | 0.19-0.74 | |||
Sex | |||||||||
Female | — | — | — | — | — | — | |||
Male | 0.56 | 0.31-1.02 | .057 | 0.75 | 0.48-1.15 | .2 | 0.69 | 0.4-1.21 | .2 |
Characteristic . | OS . | EFS . | RFS . | ||||||
---|---|---|---|---|---|---|---|---|---|
HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
Dose group, × 106CAR T cells per kg | .008 | <.001 | .002 | ||||||
0-1.3 | — | — | — | — | — | — | |||
1.3-1.7 | 0.7 | 0.34-1.46 | 0.51 | 0.29-0.88 | 0.4 | 0.19-0.82 | |||
1.7-2.4 | 0.4 | 0.18-0.87 | 0.4 | 0.22-0.73 | 0.43 | 0.2-0.89 | |||
2.4-5.1 | 0.22 | 0.08-0.61 | 0.24 | 0.12-0.49 | 0.18 | 0.07-0.49 | |||
Age at infusion, y | 0.98 | 0.94-1.03 | .4 | 0.97 | 0.94-1.00 | .085 | 0.98 | 0.94-1.03 | .4 |
Preinfusion disease burden overall | <.001 | <.001 | .004 | ||||||
High | — | — | — | — | — | — | |||
Low | 0.38 | 0.15-0.99 | 0.34 | 0.18-0.65 | 0.38 | 0.17-0.88 | |||
No detectable disease | 0.18 | 0.06-0.50 | 0.29 | 0.16-0.52 | 0.38 | 0.19-0.74 | |||
Sex | |||||||||
Female | — | — | — | — | — | — | |||
Male | 0.56 | 0.31-1.02 | .057 | 0.75 | 0.48-1.15 | .2 | 0.69 | 0.4-1.21 | .2 |